Related Experiment Video
Updated: Jun 27, 2026
09:11
Retinal Pathophysiological Evaluation in a Rat Model
Published on: May 6, 2022
Emerging drugs for diabetic retinopathy
1Gloucestershire NHS Foundation Trust, Sandford Road, Cheltenham, GL54 6AN, UK. Quresh.Mohamed@glos.nhs.uk
Expert Opinion on Emerging Drugs
|December 3, 2008
Summary
New diabetic retinopathy (DR) treatments targeting molecular mechanisms show promise for improving vision. Emerging therapies, including novel drug classes and gene silencing, offer hope for better outcomes in diabetic patients.
Area of Science:
- Ophthalmology
- Endocrinology
- Molecular Biology
Background:
- Diabetic retinopathy (DR) is a leading cause of vision loss in working-age adults, often persisting despite good diabetes management.
- Current treatments for DR, such as laser photocoagulation, have limited efficacy in improving visual outcomes for established cases.
- Research is increasingly focused on the molecular pathways underlying DR to develop targeted therapies.
Purpose of the Study:
- To review emerging therapeutic targets and treatments for diabetic retinopathy.
- To discuss novel interventions currently undergoing clinical trials for DR management.
Main Methods:
- Literature review of potential therapeutic targets for DR.
- Analysis of emerging therapies and treatments in clinical trials.
Main Results:
- Investigated therapies include aldose reductase/polyol pathway inhibitors, advanced glycation end-product inhibitors, and protein kinase C inhibitors.
- Explored strategies to reduce oxidative stress and modulate growth factors like VEGF and TNF.
- Examined novel therapeutics such as antisense oligonucleotides and small interfering RNAs in clinical trials.
Conclusions:
- Emerging treatments for diabetic retinopathy offer potential for improved efficacy and safety.
- Combination therapy with emerging treatments and standard care may enhance visual outcomes.
- These novel approaches hold promise for preventing the vision-damaging consequences of DR.
Related Concept Videos
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
01:22Diabetic Neuropathy
DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
01:28Diabetic Nephropathy
Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...